Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers
Author Information
Author(s): Kate Lawrenson, Simon Gayther
Primary Institution: EGA UCL Institute for Women's Health, University College London
Conclusion
The studies highlight the need for better molecular profiling and biomarkers to improve the understanding and treatment of ovarian cancer.
Supporting Evidence
- About 65% of women with epithelial ovarian cancer will die within five years of their diagnosis.
- There are no effective biomarkers that can identify early-stage disease.
- The studies suggest that biomarker expression is more strongly associated with histological sub-type than with disease stage.
Takeaway
Ovarian cancer is complicated, and scientists are trying to find better ways to understand and treat it by looking at different types of the disease.
Methodology
The studies involved analyzing gene expression profiles and biomarker expression in ovarian cancer samples.
Potential Biases
The study design may introduce bias due to the limited sample size and the complexity of ovarian cancer subtypes.
Limitations
The number of cases within each sub-group limits the power of the study to detect significant associations.
Participant Demographics
The studies included ovarian cancer samples from 157 patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website